Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Sep 2026 → Jan 2027
See other at-risk trials from Masonic Cancer Center, University of Minnesota

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Sep 2026 to Jan 2027
    • Study completion pushed from Feb 2027 to Feb 2028
    • Secondary endpoints: details revised at 1 of 4 entries
    • Eligibility criteria expanded, about 4 words
  2. Primary completion date: Apr 2026 to Sep 2026
    • Study completion date: Dec 2026 to Feb 2027
    v25
  3. Primary completion date: Dec 2025 to Apr 2026
    • Study completion date: Dec 2025 to Dec 2026
    v24
  4. 2 versions Re-verified since Jan 25, 2024, no change to tracked fieldsv22-v23
  5. Primary and study completion dates: Dec 2022 to Dec 2025v21
Show 19 earlier versionsHide 19 earlier versions
  1. Secondary endpoints: details revised at 2 of 4 entriesv20
  2. Re-verified, no change to tracked fieldsv19
  3. Primary and study completion dates: Dec 2019 to Dec 2022v18
  4. Primary and study completion dates: Dec 2018 to Dec 2019v17
  5. Re-verified, no change to tracked fieldsv16
  6. Primary and study completion dates: Dec 2017 to Dec 2018v15
  7. 2 versions Re-verified since Oct 4, 2017, no change to tracked fieldsv13-v14
  8. Primary and study completion dates: Dec 2016 to Dec 2017
    • Start date: Oct 2011 to Oct 20, 2011
    v12
  9. Primary completion date: Jun 2016 to Dec 2016
    • Study completion date: Aug 2016 to Dec 2016
    v11
  10. Primary completion date: Oct 2015 to Jun 2016
    • Study completion date: Dec 2015 to Aug 2016
    v10
  11. Re-verified, no change to tracked fieldsv9
  12. Interventions: Umbilical Cord Blood (UCB) Units (Biological) to Umbilical Cord Blood (UCB) (Biological)v8
  13. 3 versions Re-verified since Jul 10, 2012, no change to tracked fieldsv5-v7
  14. Eligibility criteria expanded, about 13 wordsv4
  15. Eligibility criteria expanded, about 70 wordsv3
  16. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
For the next 5-10 years or possibly longer, a high proportion of the Cord Blood Banks (CBB) inventory worldwide will be composed of unlicensed umbilical cord blood (UCB) units. While Food and Drug Administration (FDA)-licensed units will be prioritized, it will always be possible that an unlicensed unit will have known attributes, making it a better source of cells for the given indication. Because of the wide variety of current and potential indications as a source of cells for hematopoietic reconstitution or other form of cellular therapy, it is critical that the investigators have access to unlicensed UCB units.
Trial Details
NCT Number NCT01451502
Lead Sponsor Masonic Cancer Center, University of Minnesota
Conditions
(from sponsor)		 Lymphatic Diseases, Hematopoietic Malignancy
Related terms Hematologic Neoplasms, Lymphatic Diseases
Enrollment 250 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov